Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
Revenue of Rani Therapeutics Holdings, Inc. (RANI)
Revenue in 2023 (TTM): $
According to Rani Therapeutics Holdings, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Rani Therapeutics Holdings, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-822,000 | $-65,277,000 | $-67,883,000 | $-33,970,000 |
| 2022 | $ | $-1,312,000 | $-60,891,000 | $-63,274,000 | $-63,344,000 |
| 2021 | $2.72 M | $2.72 M | $-52,084,000 | $-53,047,000 | $-53,088,000 |
| 2020 | $462 K | $462 K | $-15,955,000 | $-16,668,000 | $-16,703,000 |
| 2019 | $979 K | $979 K | $-26,013,000 | $-26,587,000 | $-26,597,000 |